Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prostate-only, dose-escalated radiotherapy plus concomitant androgen deprivation therapy in NCCN high-risk MMAI low/intermediate-risk prostate cancer
2024-510707-11-00Phase 2Authorised
- Sponsor
- Linac-Pet Scan Opco
- Start
- May 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by Linac-Pet Scan Opco. Primary endpoint: Disease-free survival at 5 years. Planned start May 2024; status: authorised.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-510707-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510707-11-00.